SecBot SecBot
8-K ·Filed Jun 3, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-255396
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine governance filing, no immediate trading catalyst. Monitor future 8-K filings for actual equity grant activity under the new plan, which could signal management's confidence or retention strategy.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$52.99
T+0 close · Jun 3, 2026 · via day close
Latest settled
+13.21%
T+60 · $59.99
Vs SPY
+11.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $52.99entry
  2. T+1 · 6mo ago −2.38%α +0.22% · $51.73
  3. T+5 · 5mo ago −1.51%α +1.04% · $52.19
  4. T+20 · 4mo ago +15.04%α +16.41% · $60.96
  5. T+60 · 3mo ago +13.21%α +11.33% · $59.99

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where shareholders approved the new 2026 Equity Incentive Plan (replacing the 2014 plan), elected all eight director nominees, and approved say-on-pay and auditor appointments. The 2026 Plan authorizes up to 4.4 million new common shares plus a rollover of up to 14.72 million shares from the prior plan, providing long-term equity compensation capacity. This is a routine governance filing with no material financial impact.

Key Facts

  • Shareholders approved the 2026 Equity Incentive Plan with 58,579,810 votes for, 27,570,443 against, and 842,250 abstentions.
  • The 2026 Plan authorizes 4,400,000 new common shares plus up to 14,720,800 shares rolled over from the prior 2014 plan.
  • All eight director nominees were elected with strong support (82.5M to 86.6M votes for each).
  • Say-on-pay was approved with 82.2M votes for, 4.8M against.
  • PricewaterhouseCoopers LLP was ratified as auditor with 90.4M votes for.
  • 93.54% of outstanding common shares were represented at the meeting.
  • The 2026 Plan replaces the Amended and Restated 2014 Equity Incentive Plan.

Financial Impact

No immediate financial impact. The 2026 Plan provides up to ~19.1M shares for future equity grants, but no specific grants were disclosed.

dilution

Risk Factors

  • Potential future dilution from equity grants under the new plan, though amounts are not yet specified.
  • The 27.6M votes against the 2026 Plan (32% of votes cast) indicate notable shareholder dissent, which may signal governance concerns.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-255396
Document: xene-20260602.htm0001193125-26-255396
Document: 0001193125-26-255396-index-headers.html0001193125-26-255396
Document: 0001193125-26-255396-index.html0001193125-26-255396
Document: 0001193125-26-255396.txt0001193125-26-255396

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026